Vendor Intelligence Report: Peptides For Sale

Published 12 Jun 2026. 19-page investigative report on who is behind Peptides For Sale: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Peptides For Sale is not a fully anonymous pop-up: archive records show the domain’s history back to 2016, and corporate filings across Delaware and Tennessee tie the site to a named Johnson City operator. That attribution helps recourse, but the same record flags a not-in-good-standing entity, privacy-shielded infrastructure and mailbox usage.

Across 23 Finnrick lab tests, Peptides For Sale recorded 0 pass / 23 fail — an overall pass rate of 0%. The failures span all five tested peptide lines, so this is not a one-product miss and Finnrick cannot call any tested product a reasonable first-choice buy. Semaglutide is merely the least-poor signal while still producing no pass, and CJC-1295 is the clearest avoid signal; BPC-157 and Melanotan II do not provide a safer internal lane. Ratings contract further under stricter grading.

The report also separates testing claims from verifiable testing evidence. The homepage markets rigorous testing, but the field review found no public batch-specific COAs, no named third-party lab, no chromatograms and a testing-related link that resolves to an academic textbook abstract rather than Peptides For Sale batch data.

Peptide buyers should also weigh the catalog around the peptides. Archived and current captures show designer benzodiazepines, SARMs, prescription-drug analogues and syringes sold beside peptide products. A small promotion scan found vendor-owned X discount codes and one Reddit code placement in a benzodiazepine sourcing thread, not a broad influencer network.

Inside the full report:

  • Complete Finnrick Appendix A for five tested products, with per-product pass/fail rates and methodology-divergence charts
  • Wayback captures documenting the 2016 site history and 2023 designer-benzodiazepine catalog
  • Delaware and Tennessee corporate filings tying the site legal pages to the operating entity
  • COA-verification review, including the homepage testing claim and misdirected testing-link artifact
  • Affiliate/promotion scan covering vendor-owned X codes, Knoji coupons and the Reddit benzodiazepine-context code

Risk assessment

  • Finnrick-tested peptide quality risk — high: Finnrick tested Melanotan II, Ipamorelin, BPC-157, CJC-1295 and Semaglutide: 23 tests, 0 pass / 23 fail.
  • COA and testing-verification risk — high: The site claims rigorous testing but field review found no public batch COAs, no named lab and no chromatograms; its testing link led to an Oxford textbook abstract.
  • High-risk non-peptide catalog and regulatory-interruption risk — high: Current and archived catalogs show designer benzodiazepines, SARMs, prescription-drug analogues and syringes alongside peptides.
  • Entity standing and infrastructure-opacity risk — medium: Spectra Enterprises LLC was identifiable, but Delaware status was not in good standing and WHOIS/registrar/mailbox choices reduce buyer recourse.
  • Affiliate-promotion disclosure risk — medium: Scan found a small code/link network, including one Reddit discount-code comment, with 0 of 4 placements marked disclosed and no third-party X network.
  • Reputation and delivery-uncertainty risk — medium: Researchers noted limited scam/non-delivery complaints and social-history deletion, but no large-scale exit-scam pattern surfaced.